Meda Scoops Up Asthma Inhaler Maker For $135M

Law360, New York (August 30, 2013, 1:54 PM EDT) -- Swedish pharmaceutical company Meda AB will buy Acton Pharmaceuticals Inc. for $135 million, an addition driven largely by the Massachusetts company's newly approved steroid-containing asthma inhaler, it said Friday.

Acton's Aerospan, an inhaler set to hit the U.S. market at the beginning of next year, is Meda's key to the nation's $2 billion market for inhaled asthma products containing a mono-corticosteroid, as well as other major markets, according to Meda. Aerospan falls within one of Meda's core therapy areas, respiratory, the company said.

"The acquisition of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.